• Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

    • November 21, 2018
    • Posted By : admin
    • 0 Comment

    Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch of reSET® for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available.

    Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence in substances of abuse and increased retention as compared to outpatient therapy alone. The reSET therapeutic content was validated in a randomized clinical trial through the National Institute of Drug Abuse (NIDA) Clinical Trial Network.

    reSET is a 12-week (90-day) prescription digital therapeutic to be used in conjunction with outpatient clinician-delivered care. reSET offers interactive treatment modules that deliver cognitive behavioral therapy and fluency training to reinforce proficiency. Within the clinician dashboard, clinicians can follow patient-reported substance use, cravings, and triggers to facilitate transparency and deeper interaction between patients and clinicians at face-to-face meetings.

    “We all have a role to play in helping find solutions that work for patients, families and communities as we fight the substance abuse epidemic,” said Richard Francis, CEO, Sandoz. “Adding reSET to outpatient therapy enhances behaviors associated with recovery. It leverages new technology to help patients improve abstinence in substances of abuse and stay in treatment programs longer than outpatient therapy alone.”

    “Patients with Substance Use Disorder deserve access to more effective, convenient, and innovative treatment options,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. “reSET has been clinically validated to significantly improve outcomes for patients, while also providing patients a discreet way to access care when and where they need it. Prescription digital therapeutics will help redefine the treatment of serious diseases like Substance Use Disorder, providing improved patient outcomes, and driving clinical insights for clinicians.”


You Might Also Like

No comments found



error: Content is protected !!